Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Post by Ingiboyon Apr 01, 2024 12:12pm
137 Views
Post# 35963002

Do we understand what we are voting on ?

Do we understand what we are voting on ?I am not sure about the rest of you but I am confused on how this "new company" will work. So many questions unanswered in this LOI.

1. Are our shares being transferred to this new company 1 for 1 with the existing Replicel share ownership structure?

2.  Andrew Schutte's new company purchases all Replicel assets (for nothing) and offers the share holders an 8% Royalty on all future profits up to a maximum of $160,922,238.  So we are lead to believe somewhere in the distant future we will see some return on our investment.  Meanwhile if I am not mistaken he retains all other profits (92%) Is that correct ?

3.  The LOI is confusing because it also states the following:
"an 8-per-cent royalty on all gross profits earned by the purchaser in relation to the sale of DermaPrecise, RCH, RCT and RCS, or their improvements, after completion of the proposed transaction......."
Is Andrew once getting control of all the assets going to quickly sell them and give the shareholders an 8% Royalty ? 

4. Who are the other shareholders in his new company ?

5. When do we receive the Computershare information package?

6. Does Andrew and his cronies actually think we are buying into this BS ?

7.  Are there any other companies looking at this hostile takeover and thinking of placing a counter offer for the company ?

 




<< Previous
Bullboard Posts
Next >>